Allogene Therapeutics Inc (ALLO)

Mar 13, 2025, 11:56 PM EDT - 20 days ago

Allogene Therapeutics, Inc. (ALLO) Q4 2024 Earnings Call Transcript

Mar 13, 2025, 4:02 PM EDT - 20 days ago

Allogene Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update

Mar 3, 2025, 8:30 AM EST - 4 weeks ago

Allogene Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update

Feb 26, 2025, 10:52 AM EST - 5 weeks ago

Allogene: Assessing The Pipeline, Competitive Landscape, And Opportunities

Feb 26, 2025, 8:30 AM EST - 5 weeks ago

Allogene Therapeutics Announces Participation in March Investor Conference

Feb 25, 2025, 4:10 PM EST - 5 weeks ago

Allogene Therapeutics Expands Strategic Partnership with Foresight Diagnostics to Advance Joint Development Activities Outside the US Across Europe, UK, Canada, and Australia

Feb 24, 2025, 10:53 PM EST - 5 weeks ago

Allogene Therapeutics: Disrupting CAR-T With A Scalable Model

Feb 13, 2025, 4:30 PM EST - 6 weeks ago

Allogene Therapeutics Announces Publication of Durable Response Data from Phase 1 ALPHA/ALPHA2 Trials of the Allogeneic CAR T Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma in the Journal of Clinical Oncology

Jan 28, 2025, 8:30 AM EST - 2 months ago

Allogene Therapeutics Secures U.S. FDA IND Clearance for ALLO-329, Advancing its Next-Generation Allogeneic CAR T into Autoimmune Diseases

Dec 16, 2024, 8:30 AM EST - 3 months ago

Allogene Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 12, 2024, 8:30 AM EST - 3 months ago

Allogene Therapeutics Acknowledges the Passing of Founding Board Member David Bonderman

Nov 19, 2024, 8:30 AM EST - 4 months ago

Allogene Therapeutics Announces Participation in December Investor Conferences

Nov 18, 2024, 8:30 AM EST - 4 months ago

Allogene Therapeutics Presents Preclinical Data for ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Disease at the American College of Rheumatology (ACR) Convergence

Nov 7, 2024, 8:59 PM EST - 5 months ago

Allogene Therapeutics, Inc. (ALLO) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 4:02 PM EST - 5 months ago

Allogene Therapeutics Reports Third Quarter 2024 Financial Results and Business Update

Nov 7, 2024, 10:00 AM EST - 5 months ago

Allogene Therapeutics Announces Positive Phase 1 Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Patients with Advanced Renal Cell Carcinoma at SITC and IKCS

Nov 5, 2024, 9:10 AM EST - 5 months ago

Allogene Therapeutics to Present New Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Adult Patients with CD70 Positive Advanced Renal Cell Carcinoma (RCC) at the International Kidney Cancer Symposium (IKCS) and Society for Immunotherapy of Cancer (SITC) Annual Meeting

Oct 30, 2024, 8:30 AM EDT - 5 months ago

Allogene Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update

Oct 2, 2024, 4:11 PM EDT - 6 months ago

Allogene Therapeutics (ALLO) Stock Drops Over 5% Amid Market Activity

Sep 30, 2024, 8:30 AM EDT - 6 months ago

Allogene Therapeutics Announces Participation in the Goldman Sachs Cell Therapy Day Conference

Aug 26, 2024, 11:39 PM EDT - 7 months ago

Allogene Therapeutics: Cema-Cel Promising Among Innovative CAR T-Cell Therapies

Aug 10, 2024, 12:34 AM EDT - 8 months ago

Allogene Therapeutics, Inc. (ALLO) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 8:30 AM EDT - 8 months ago

Allogene Therapeutics Announces Participation in Upcoming Investor Conferences

Aug 7, 2024, 4:02 PM EDT - 8 months ago

Allogene Therapeutics Reports Second Quarter 2024 Financial Results and Business Update

Jul 31, 2024, 8:30 AM EDT - 8 months ago

Allogene Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update

Jul 1, 2024, 8:30 AM EDT - 9 months ago

Allogene Therapeutics Activates Three Community Cancer Centers as First Sites for the Pivotal Phase 2 ALPHA3 Trial Evaluating Cemacabtagene Ansegedleucel (cema-cel) as First Line (1L) Consolidation Treatment for Patients with Large B-Cell Lymphoma (LBCL)

Jun 20, 2024, 8:30 AM EDT - 10 months ago

Allogene Therapeutics Initiates Pivotal Phase 2 Trial Investigating Cemacabtagene Ansegedleucel (cema-cel), an Allogeneic CAR T Product, as Part of First Line Treatment for Patients with Large B-Cell Lymphoma (LBCL) Likely to Relapse

Jun 12, 2024, 1:09 PM EDT - 10 months ago

Allogene: Two End Of 2024 Data Readouts With Improved Allogeneic CAR-T Products

May 23, 2024, 8:30 AM EDT - 11 months ago

Allogene Therapeutics Announces Participation in the TD Cowen 5th Annual Oncology Innovation Summit

May 13, 2024, 7:31 PM EDT - 11 months ago

Allogene Therapeutics, Inc. (ALLO) Q1 2024 Earnings Call Transcript

May 13, 2024, 4:47 PM EDT - 11 months ago

Allogene Therapeutics Announces Pricing of $110 million Offering of Common Stock

May 13, 2024, 4:01 PM EDT - 11 months ago

Allogene Therapeutics Reports First Quarter 2024 Financial Results and Business Update

May 6, 2024, 8:30 AM EDT - 11 months ago

Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update

Apr 26, 2024, 8:30 AM EDT - 1 year ago

Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell Carcinoma

Apr 9, 2024, 8:30 AM EDT - 1 year ago

Allogene Therapeutics Announces Q2 Investor Conference Participation

Apr 4, 2024, 11:30 AM EDT - 1 year ago

Showcasing Seeking Alpha's March 2024 New Analysts

APD AXP CPS CPT DG DK EPR

Mar 14, 2024, 8:49 PM EDT - 1 year ago

Allogene Therapeutics, Inc. (ALLO) Q4 2023 Earnings Call Transcript

Mar 14, 2024, 4:05 PM EDT - 1 year ago

Allogene Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update

Mar 12, 2024, 8:30 AM EDT - 1 year ago

Allogene Therapeutics and Arbor Biotechnologies Announce Global Gene Editing Licensing Agreement to Support Advancement of Next-Generation Allogeneic CAR T Platform in Autoimmune Disease

Mar 5, 2024, 8:30 AM EST - 1 year ago

Allogene Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update

Feb 28, 2024, 8:30 AM EST - 1 year ago

Allogene Therapeutics Announces Participation in the 44th Annual TD Cowen Health Care Conference

Feb 16, 2024, 8:30 AM EST - 1 year ago

Allogene Therapeutics to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments Related to the December 2020 Formation of the Allogene Overland Biopharm Joint Venture in Asia

Jan 5, 2024, 8:15 AM EST - 1 year ago

Allogene to cut 22% of its workforce

Jan 4, 2024, 4:15 PM EST - 1 year ago

Allogene Therapeutics and Foresight Diagnostics Announce Partnership to Develop MRD-based In-Vitro Diagnostic for Use in ALPHA3, the First Pivotal Trial for Frontline Consolidation in Large B-Cell Lymphoma

Jan 4, 2024, 4:05 PM EST - 1 year ago

Allogene Therapeutics Announces 2024 Platform Vision to Redefine the Future of CAR T Led by ALPHA3, the Industry's First Pivotal Trial for Frontline Consolidation in Large B-Cell Lymphoma

Jan 3, 2024, 4:05 PM EST - 1 year ago

Allogene Therapeutics to Host Conference Call Previewing its 2024 Platform Vision and Present at the 42nd Annual J.P. Morgan Healthcare Conference

Dec 9, 2023, 12:00 PM EST - 1 year ago

Allogene Therapeutics Presents Comprehensive Safety Data of Proprietary Lymphodepletion Agent ALLO-647 at the 65th Annual Meeting of the American Society of Hematology

Dec 1, 2023, 8:30 AM EST - 1 year ago

Allogene Therapeutics Announces Participation in December Investor Conference

Nov 3, 2023, 12:00 PM EDT - 1 year ago

Allogene Therapeutics Presents Preclinical Data on Next Generation Cloak™ and Dagger™ Technologies at the Society for Immunotherapy of Cancer Annual Meeting

Nov 3, 2023, 12:00 PM EDT - 1 year ago

Allogene Therapeutics Presents Preclinical Data on a Novel Allogeneic CAR T Product Candidate Targeting Claudin18.2 at the Society for Immunotherapy of Cancer Annual Meeting